Market closedNon-fractional
BioAtla/BCAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Ticker
BCAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
65
Website
www.bioatla.com
BioAtla Metrics
BasicAdvanced
$82M
Market cap
-
P/E ratio
-$2.49
EPS
1.21
Beta
-
Dividend rate
Price and volume
Market cap
$82M
Beta
1.21
Financial strength
Current ratio
4.487
Quick ratio
4.186
Long term debt to equity
0.835
Total debt to equity
3.87
Management effectiveness
Return on assets (TTM)
-53.28%
Return on equity (TTM)
-115.68%
Valuation
Price to book
1.65
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-0.726
Growth
Earnings per share change (TTM)
-5.85%
3-year earnings per share growth (CAGR)
23.97%
What the Analysts think about BioAtla
Analyst Ratings
Majority rating from 5 analysts.
BioAtla Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$23M
-13.75%
Profit margin
0.00%
NaN%
BioAtla Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.75
-$0.70
-$0.56
-$0.48
-
Expected
-$0.64
-$0.80
-
-$0.54
-$0.44
Surprise
17.19%
-12.50%
-
-11.44%
-
BioAtla News
AllArticlesVideos
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
GlobeNewsWire·1 day ago
3 Penny Stocks With 735% Average Upside, According to Wall Street
24/7 Wall Street·2 weeks ago
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioAtla stock?
BioAtla (BCAB) has a market cap of $82M as of July 27, 2024.
What is the P/E ratio for BioAtla stock?
The price to earnings (P/E) ratio for BioAtla (BCAB) stock is 0 as of July 27, 2024.
Does BioAtla stock pay dividends?
No, BioAtla (BCAB) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next BioAtla dividend payment date?
BioAtla (BCAB) stock does not pay dividends to its shareholders.
What is the beta indicator for BioAtla?
BioAtla (BCAB) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell BioAtla stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.